5-Amino-1MQ

Overview

5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in white adipose tissue and certain cancers. By blocking NNMT, 5-Amino-1MQ reroutes methyl groups and nicotinamide back into salvage pathways that regenerate NAD+ and SAM, two key metabolic cofactors. Although small in size, it sits at the intersection of NAD+ biology and adipocyte signaling, which is why research interest has grown alongside broader metabolic peptide work.

In preclinical obesity models, NNMT inhibition has been associated with reduced adiposity, improved insulin sensitivity, and lowered lipogenesis without meaningful changes in food intake. These findings led to 5-Amino-1MQ becoming a frequently discussed research compound in longevity and body composition communities, often alongside metabolic peptides such as MOTS-c, FGF21, and Klotho.

Because 5-Amino-1MQ is a quaternary ammonium small molecule rather than a peptide, it has distinct pharmacokinetic and formulation considerations. It is catalogued here alongside peptides because it is commonly cross-listed on peptide research catalogs and is studied in the same metabolic contexts as agents like Tesofensine and Cagrilintide.

Structure / Chemistry

5-Amino-1MQ is a small heterocyclic compound based on a methylated quinolinium scaffold with an amino substituent at the 5-position. Its positive charge at physiological pH and modest molecular weight distinguish it from the peptide drugs often studied in the same metabolic contexts. Structurally, it acts as a substrate-mimetic inhibitor of NNMT rather than a receptor ligand.

Mechanism of Action

NNMT transfers a methyl group from SAM (S-adenosylmethionine) to nicotinamide, producing 1-methylnicotinamide and SAH. Overactive NNMT drains the SAM methyl pool and consumes nicotinamide that would otherwise be recycled into NAD+. 5-Amino-1MQ competitively blocks this reaction. The downstream effects studied in animal models include higher cellular NAD+, increased SAM-dependent methylation capacity, and altered expression of lipogenic and thermogenic programs in adipose tissue.

Research Summary

Pharmacokinetics

Preclinical studies in rodents report oral bioavailability and systemic exposure sufficient for once-daily dosing regimens at research doses. Reported elimination half-life in mouse models is on the order of several hours. As a charged small molecule, tissue distribution and renal clearance are key pharmacokinetic considerations. Human pharmacokinetic data remain limited and 5-Amino-1MQ is used strictly as a research tool.

Common Discussion Topics

• Whether NNMT inhibition translates to meaningful human fat loss outside rodent models.
• Interactions between NNMT inhibition and NAD+ precursors such as NR and NMN.
• Stacking questions alongside incretin mimetics like Semaglutide or Tirzepatide.
• Formulation and stability in oral vs. injectable research preparations.
• Long-term safety unknowns given the enzyme's roles beyond adipocytes.

Related Compounds

• MOTS-c
• FGF21
• Klotho
• NAD Precursors
• Tesofensine